Evidence map›Paper›PMID 37732386›Full record

ArticleJournal of feline medicine and surgery2023

Retrospective study and outcome of 307 cats with feline infectious peritonitis treated with legally sourced veterinary compounded preparations of remdesivir and GS-441524 (2020-2022).

Samantha S Taylor, Sally Coggins, Emi N Barker, Danièlle Gunn-Moore, Kamalan Jeevaratnam, Jacqueline M Norris, David Hughes, Emily Stacey, Laura MacFarlane, Carolyn O'Brien and 18 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of feline medicine and surgery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 1 pooled it
9.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Immunomodulatory Effects ofInternational journal of molecular sciences · 2026
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 11 institutions in 2 countries.

Samantha S TaylorInternational Society of Feline Medicine, Tisbury, UK.ORCID 0000-0002-8668-0777
Sally CogginsUniversity of Sydney, Sydney, NSW, Australia.
Emi N BarkerLangford Vets, University of Bristol, Langford, UK.ORCID 0000-0001-6293-6662
Danièlle Gunn-MooreR(D)SVS & Roslin Institute, University of Edinburgh, Edinburgh, UK.
Kamalan JeevaratnamUniversity of Surrey, Guildford, UK.
Jacqueline M NorrisUniversity of Sydney, Sydney, NSW, Australia.
David HughesConcord Veterinary Hospital, Sydney, NSW, Australia.
Emily StaceyGoddard Veterinary Group, London, UK.ORCID 0000-0001-8350-5570
Laura MacFarlaneNorth Downs Specialist Referrals, Bletchingley, UK.
Carolyn O'BrienMelbourne Cat Clinic, Melbourne, VIC, Australia.
Rachel KormanCat Specialist Services, Underwood, QLD, Australia.
Gerard McLauchlanAura Veterinary, Guildford, UK.ORCID 0000-0003-3209-9327
Xavier Salord TorresLumbry Park Veterinary Specialists, Alton, UK.
Aimee TaylorLangford Vets, University of Bristol, Langford, UK.
Jos BongersUniversity of Glasgow, Glasgow, UK.
Laura Espada CastroUniversity of Glasgow, Glasgow, UK.
Max ForemanDick White Referrals, Cambridge, UK.ORCID 0000-0002-2381-1389
James McMurroughVets Now Manchester, Manchester, UK.
Bethany ThomasVets Now Manchester, Manchester, UK.ORCID 0009-0000-7856-1404
Emilie RoyauxDavies Veterinary Specialists, Hitchin, UK.
Isabel Calvo SaizSouthfields Veterinary Specialists, Basildon, UK.
Guido BertoldiSouthfields Veterinary Specialists, Basildon, UK.
Caroline HarlosAniCura Djursjukhuset Albano, Stockholm, Sweden.
Megan WorkWillows Veterinary Centre and Referral Service, Shirley, UK.ORCID 0000-0002-2124-7841
Cameron PriorWillows Veterinary Centre and Referral Service, Shirley, UK.ORCID 0000-0002-5254-3205
Stephanie SorrellIdexx, Wetherby, UK.ORCID 0000-0001-6458-7806
Richard MalikUniversity of Sydney, Sydney, NSW, Australia.
Séverine TaskerLinnaeus Veterinary Limited, Shirley, UK.
The University of Sydney · AUUniversity of Bristol · GBWillows Veterinary Centre and Referral Service · GBUniversity of Glasgow · GBUniversity of Surrey · GBAnimal Free Research UK · GBConcord Repatriation General Hospital · AUMelbourne Clinic · AUNorth Downs Hospital · GBRoslin Institute · GBServices Australia · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesFeline infectious peritonitis (FIP) is a serious disease that arises due to feline coronavirus infection. The nucleoside analogues remdesivir and GS-441524 can be effective in its treatment, but most studies have used unregulated products of unknown composition. The aim of the present study was to describe the treatment of FIP using legally sourced veterinary-prescribed regulated veterinary compounded products containing known amounts of remdesivir (injectable) or GS-441524 (oral tablets).

methodsCats were recruited via email advice services, product sales contacts and study publicity. Cats were excluded if they were deemed unlikely to have FIP, were not treated exclusively with the veterinary compounded products, or if there was a lack of cat and/or treatment (including response) data. Extensive cat and treatment data were collected.

resultsAmong the 307 cats recruited, the predominant type of FIP was most commonly abdominal effusive (49.5%) and then neurological (14.3%). Three treatment protocols were used; remdesivir alone (33.9%), remdesivir followed by GS-441524 (55.7%) and GS-441524 alone (10.4%). The median (range) initial treatment period duration and longest follow-up time point after starting treatment were 84 (1-330) days and 248 (1-814) days, respectively. The most common side effect was injection pain (in 47.8% of those given subcutaneous remdesivir). Of the 307 cats, 33 (10.8%) relapsed, 15 (45.5%) during and 18 (54.5%) after the initial treatment period. At the longest follow-up time point after completion of the initial treatment period, 84.4% of cats were alive. The cats achieving a complete response within 30 days of starting treatment were significantly more likely to be alive at the end of the initial treatment period than those cats that did not. CONCLUSIONS AND RELEVANCE: Legally sourced remdesivir and GS-441524 products, either alone or used sequentially, were very effective in the treatment of FIP in this group of cats. Variable protocols precluded statistical comparison of treatment regimens.

Indexed as

Cat DiseasesCoronavirus InfectionsFeline Infectious PeritonitisAdenosineAdenosine MonophosphateAlanineAnimalsCatsRetrospective StudiesAdenosineAdenosine MonophosphateAlanineGS-441524remdesivirantiviralcoronavirusnucleoside analogueSurvival

Identifiers

PMID37732386
PMCPMC10812036
OpenAlexW4386910436

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.